RT Journal Article T1 Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry A1 Balaz, David A1 Wikman Jorgensen, Philip Erick A1 Galvañ, Vicente Giner A1 Rubio Rivas, Manuel A1 de Miguel Campo, Borja A1 López, Mariam Noureddine A1 López Caleya, Juan Francisco A1 Huelgas, Ricardo Gómez A1 Pesqueira Fontán, Paula María A1 Bailón, Manuel Méndez A1 Fernández Garcés, Mar A1 Fernández Cruz, Ana A1 García García, Gema María A1 Rhyman, Nicolás A1 Corral Gudino, Luis A1 Rodríguez Mancheño, Aquiles Lozano A1 De La Chica, María Navarro A1 Torregrosa García, Andrea A1 Alcalá, José Nicolás A1 Díaz Jiménez, Pablo A1 Royo Trallero, Leticia Esther A1 Comas Casanova, Pere A1 Millán Núñez-Cortés, Jesús A1 Casas Rojo, José Manuel AB Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7–160) vs. 49.3 (16–109) mg/dL; p < 0.001), ferritin (791 (393–1534) vs. 470 (236–996) µg/dL; p < 0.001), D dimer (750 (430–1400) vs. 617 (345–1180) µg/dL; p < 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation